PeopleBio Inc
PeopleBio, Inc., a biotech company, engages in developing diagnostics for protein misfolding diseases worldwide. Its Multimer Detection System technology uses capturing antibodies and epitope-overlapping detection antibodies for the detection of oligomers or multimers from monomers in protein-misfolding diseases. The company has strategic collaborations with Seoul National University Bundang Hosp… Read more
PeopleBio Inc (304840) - Total Assets
Latest total assets as of September 2025: ₩19.75 Billion KRW
Based on the latest financial reports, PeopleBio Inc (304840) holds total assets worth ₩19.75 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PeopleBio Inc - Total Assets Trend (2017–2024)
This chart illustrates how PeopleBio Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PeopleBio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
PeopleBio Inc's total assets of ₩19.75 Billion consist of 63.1% current assets and 36.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.26 Billion | 4.7% |
| Accounts Receivable | ₩2.89 Billion | 10.7% |
| Inventory | ₩2.70 Billion | 10.0% |
| Property, Plant & Equipment | ₩2.45 Billion | 9.1% |
| Intangible Assets | ₩2.28 Billion | 8.4% |
| Goodwill | ₩379.86 Million | 1.4% |
Asset Composition Trend (2017–2024)
This chart illustrates how PeopleBio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PeopleBio Inc's current assets represent 63.1% of total assets in 2024, a decrease from 79.9% in 2017.
- Cash Position: Cash and equivalents constituted 4.7% of total assets in 2024, down from 12.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 2.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 10.7% of total assets.
PeopleBio Inc Competitors by Total Assets
Key competitors of PeopleBio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medilines Distributors Inc
PSE:MEDIC
|
Philippines | ₱4.32 Billion |
|
InBody Co.Ltd
KQ:041830
|
Korea | ₩318.34 Billion |
|
MEDIANA Co.Ltd
KQ:041920
|
Korea | ₩147.44 Billion |
|
Value Added Technology Co. Ltd
KQ:043150
|
Korea | ₩658.61 Billion |
|
MEKICS Co Ltd
KQ:058110
|
Korea | ₩55.71 Billion |
|
Meta Biomed Co. Ltd
KQ:059210
|
Korea | ₩180.11 Billion |
|
INFINITT Healthcare Co. Ltd
KQ:071200
|
Korea | ₩229.14 Billion |
|
i-SENS Inc
KQ:099190
|
Korea | ₩583.47 Billion |
PeopleBio Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PeopleBio Inc generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PeopleBio Inc is currently not profitable relative to its asset base.
PeopleBio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.70 | 1.17 | 19.91 |
| Quick Ratio | 0.49 | 1.02 | 19.58 |
| Cash Ratio | 0.00 | 0.04 | 0.00 |
| Working Capital | ₩-4.47 Billion | ₩ 2.88 Billion | ₩ 9.59 Billion |
PeopleBio Inc - Advanced Valuation Insights
This section examines the relationship between PeopleBio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.8% |
| Total Assets | ₩27.07 Billion |
| Market Capitalization | $5.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values PeopleBio Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: PeopleBio Inc's assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for PeopleBio Inc (2017–2024)
The table below shows the annual total assets of PeopleBio Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩27.07 Billion | -1.83% |
| 2023-12-31 | ₩27.58 Billion | -34.82% |
| 2022-12-31 | ₩42.32 Billion | -17.59% |
| 2021-12-31 | ₩51.35 Billion | +381.91% |
| 2020-12-31 | ₩10.65 Billion | +144.53% |
| 2019-12-31 | ₩4.36 Billion | -33.18% |
| 2018-12-31 | ₩6.52 Billion | +174.05% |
| 2017-12-31 | ₩2.38 Billion | -- |